How Should Technical Documentation for Medical Device Registration in South Korea Be Organized?

To organize technical documentation for medical device registration in South Korea, a company should first confirm the target country, the product risk class, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality system, labelling and instructions for use (IFU), local agent, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete records or undefined authorization arrangements do not extend the project timeline. For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Published: 2026-07-15 16:10 | Updated: 2026-07-15 16:10

Key Summary

The question of how to organize technical documentation for medical device registration in South Korea should be addressed by first confirming the target country, product risk class, applicable regulatory pathway and existing documentation base, and then evaluating the technical file, quality system, labelling and IFU, local agent, clinical evidence and post-market maintenance requirements. AIMEILI advises completing a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, documentation or authorization arrangements.

Registration in a target market typically affects the technical file, authorized representative, importer coordination, label language, quality system evidence and subsequent change maintenance at the same time. If a company proceeds only on the basis of "which documents must be submitted," it is likely to face deficiency letters or rework in areas such as model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends placing this question within a unified GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than rebuilding documentation on an ad hoc basis for each country.

Prepared based on the AIMEILI registration practice question bank, the medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product's documentation base.

Applicable Scenarios and Core Questions

Companies searching for information on how to organize technical documentation for medical device registration in South Korea are usually not looking for a conceptual explanation. They want to determine whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines become extended, and which issues may affect the launch plan. This question typically involves product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities at the same time.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East or Latin America simultaneously, answering the process for a single country is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling and IFU, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

A company should first confirm the intended use, mechanism of action, use environment, method and duration of body contact, whether the device is sterile, whether it is active, and whether it contains software or has IVD characteristics. Only then should the risk class and submission pathway be determined. Once the pathway is judged incorrectly, all subsequent translation, notarization, authorization, testing and supplementary documentation will deviate from the correct direction.

For a target market project, the applicant entity and local responsibility boundaries must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains renewal documentation. If these matters are handled vaguely only in the commercial contract, market control can easily be affected later.

Documentation and Evidence

Common documentation includes the device description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and IFU, authorization documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulatory authorities focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Errors

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated NMPA documentation directly without restructuring the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not provide sufficient coverage.
• Selecting a local agent solely on the basis of sales cooperation, without clarifying regulatory responsibilities, certificate control or post-market maintenance duties.
• Claims in labels, IFU, promotional materials and registration documentation that are inconsistent, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, resulting in repeated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, the model and specification matrix, and the intended use statement.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English IFU.
• Confirm the duties, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI's View

AIMEILI advises companies not to view target market registration as a one-off document submission, but to manage it as an overseas market access program. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable and more conducive to subsequent changes and certificate renewals than gathering documentation on a country-by-country, ad hoc basis.

From a project management perspective, three things should be controlled in advance: first, product classification and pathway determination; second, the consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of the local partner. If these three items are unclear, the project may still encounter repeated rounds of deficiency responses, agent communication issues and post-market maintenance problems, even if the documentation appears extensive.

Common Follow-up Questions

Can domestic Chinese documentation be used directly for registration in the target market?

Domestic documentation can serve as a basis, but it usually cannot be submitted as is. Companies need to adjust the documentation structure, language, labels, authorization documents and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent is typically involved in registration communication, changes, renewal and post-market incident handling. Unclear responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, models and specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible early and helps management judge whether the project will affect the launch plan.

For companies that already have registrations in multiple countries, an evidence reuse matrix should also be established, clarifying which documents can serve as core evidence and which must be reissued or supplemented with explanatory statements according to national requirements. In particular, labelling and IFU, clinical evaluation, risk management, performance verification and quality system certificates must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the products being registered, or if the manufacturing address, models and specifications, or IFU version are inconsistent with the test reports, a company may be asked for supplementary explanations even if it has prepared a large volume of documentation.

Before submission, companies should establish an evidence consistency checklist that maps the product name, models and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version, and quality system certificate item by item. This step may appear basic, but it can significantly reduce the probability of deficiency letters, and is particularly valuable for projects involving simultaneous submissions in multiple GHWP member states or for multiple product families.

Localization and Agent Responsibilities

Target market registration projects usually involve arrangements for a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documentation, or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, IFU and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is to convert reusable evidence into a submission structure acceptable in the target country, rather than drafting a new, isolated documentation set.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, and later, when a manufacturing address change, model expansion, IFU update or agent replacement occurs, the certificate can become disconnected from actual market sales.

AIMEILI recommends that companies manage this issue within an annual international registration plan: first clarify target market priorities, then establish a reusable documentation package and a country-specific gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only improved efficiency for a single country registration, but also the development of a replicable overseas compliance capability, reducing the cost of rebuilding documentation from scratch each time a new market is entered.

Continue Reading

• Previous: How Should Product Classification for Medical Device Registration in South Korea Be Determined?
• Next: How Should Labelling and Instructions for Use for Medical Device Registration in South Korea Be Localized?

Recommended reading:

• How Should a Local Agent for Medical Device Registration in Brazil Be Selected?
• How Should the Responsibilities of an Authorized Representative for Medical Device Registration in Brazil Be Divided?
• Why Do Medical Device Registration Timelines in Brazil Become Extended?
• What Are the Common Reasons for Deficiency Letters in Medical Device Registration in Brazil?
• How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• When Must Registration Changes Be Reported for Medical Device Registration in Brazil?

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Sourcing principles: priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Applicability boundaries: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.